Multiple sclerosis therapy monitoring based on gene expression

Current Pharmaceutical Design

Volumn 12, Issue 29, 2006, Pages 3761-3779

  Goertsches, Robert ^a   Serrrano Fernández, Pablo ^b   Möller, Steffen ^a   Koczan, Dirk ^a   Zettl, Uwe K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Autoimmune disease; cDNA microarray; Gene expression profiling; Multiple sclerosis; PBMC; Therapy response

Indexed keywords

INTERFERON BETA SERINE; RNA; TRANSCRIPTOME;

AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; DEGENERATIVE DISEASE; DRUG RESPONSE; GENE EXPRESSION; GENE IDENTIFICATION; GENOME; HUMAN; IMMUNOMODULATION; INFECTION; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATHOGENICITY; PATIENT CODING; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; TISSUE REPAIR;

BIOLOGICAL MARKERS; BIOLOGICAL RESPONSE MODIFIERS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; CYTOKINES; DRUG MONITORING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; LEUKOCYTES, MONONUCLEAR; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATIENT SELECTION; PHARMACOGENETICS; RNA, MESSENGER; TIME FACTORS;

EID: 33749847098     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778559786     Document Type: Review

References (165)

1. Ibrahim SM, Gold R. Genomics, proteomics, metabolomics: what is in a word for multiple sclerosis? Curr Opin Neurol 2005; 18(3): 231-5.
2. Karpuj MV, Steinman L, Oksenberg JR. Multiple sclerosis: a polygenic disease involving epistatic interactions, germline rearrangements and environmental effects. Neurogenetics 1997; 1(1): 21-8.
3. Pennacchio LA, Rubin EM. Comparative genomic tools and databases: providing insights into the human genome. J Clin Invest 2003; 111(8): 1099-106.
4. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50(3): 701-8.
5. Paty DW, Li DK, UBC MS/MR1 Study Group, IFNB multiple sclerosis study group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized double-blind, placebo-controlled trial. Neurology 1993; 43(4): 662-7.
6. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39(3): 285-94.
7. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997; 349(9052): 589-93.
8. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 352(9139): 1498-504.
9. Vergelli M, Hemmer B, Utz U, Vogt A, Kalbus M, Tranquill L, et al. Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87-99). Eur J Immunol 1996; 26(11): 2624-34.
10. The Chipping Forecast II. Nat Genet 2002; 32: 461-552.
11. Guttmacher AE, Collins FS. Genomic medicine - A primer. N Engl J Med 2002; 347(19): 1512-20.
12. Stürzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003; 126(6): 1419-29.
13. Wandinger KP, Lunemann JD, Wengert 0, Bellmann-Strobl J, Aktas O, Weber A, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003; 361(9374): 2036-43.
14. Baranzini SE, Mousavi P, Rio J, Caillier SJ, Stillman A, Villoslada P, et al. Transcription-based prediction of response to IFNbeta using supervised computational methods. PLoS Biol 2005; 3(1): e2.
15. Kornek B, Lassmann H. Neuropathology of multiple sclerosis-new concepts. Brain Res Bull 2003; 61(3): 321-6.
16. Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7(3): 115-21.
17. Bitsch A, Kuhlmann T, Stadelmann C, Lassmann H, Lucchinetti C, Bruck W. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol 2001; 49(6): 793-6.
18. Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. Early onset multiple sclerosis: a longitudinal study. Neurology 2002: 59(7): 1006-10.
19. Blevins G, Martin R. Future immunotherapies in multiple sclerosis. Semin Neurol 2003; 23(2): 147-58.
20. Bomprezzi R, Kovanen PE, Martin R. New approaches to investigating heterogeneity in complex traits. J Med Genet 2003; 40(8): 553-9.
21. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338(5): 278-85.
22. Traugott U, Reinherz EL, Raine CS. Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science 1983; 219(4582): 308-10.
23. Hauser SL, Bhan AK, Gilles F, Kemp M, Kerr C, Weiner HL. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 1986; 19(6): 578-87.
24. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA. Gamma delta Tcell receptor repertoire in acute multiple sclerosis lesions. Proc Natl Acad Sci USA 1992; 89(10): 4588-92.
25. Prineas JW, Wright RG. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 1978; 38(4): 409-21.
26. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996; 6(3): 259-74.
27. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47(6): 707-17.
28. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain 1997; 120(5): 865-916.
29. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. New Engl J Med 2000; 343(13): 938-52.
30. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002; 3(4): 291-301.
31. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001; 2(9): 762-4.
32. Steinman L, Zamvil S. Transcriptional analysis of targets in multiple sclerosis. Nat Rev Immunol 2003; 3(6): 483-92.
33. Hafler DA. Multiple sclerosis. J Clin Invest 2004; 113(6): 788-94.
34. Davidson A, Diamond B. Autoimmune diseases. New Engl J Med 2001; 345(5): 340-50.
35. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.
36. Oksenberg JR, Baranzini SE, Barcellos LF, Hauser SL. Multiple sclerosis: genomic rewards. J Neuroimmunol 2001; 113(2): 171-84.
37. Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E, et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003; 72(3): 710-6.
38. Villoslada P, Barcellos LF, Rio J, Begovich AB, Tintore M, Sastre-Garriga J, et al. The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta. J Neuroimmunol 2002; 130(1-2): 194-201.
39. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004; 3(2): 104-10.
40. Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol 2001; 2(9): 797-801.
41. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, Madsen L, et al. A functional and structural basis for TCR crossreactivity in multiple sclerosis. Nat Immunol 2002; 3(10): 940-3.
42. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199(7):971-9.
43. + T cells in the cerebrospinal fluid from multiple sclerosis patients. Brain 2002; 125(3): 538-50.
44. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003; 206(2):165-71.
45. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993; 6(4): 382-427.
46. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002; 104(3): 182-91.
47. Ebers GC, Sadovnick AD. Epidemiology. In: Paty DW, Ebers GC Eds, Multiple Sclerosis. Philadelphia, FA Davis Company 1998; 5-28.
48. Sadovnick AD, Armstrong H, Rice GP, Bulman D, Hashimoto L, Paty DW, et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol 1993; 33(3): 281-5.
49. Willer CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GC. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci USA 2003; 100(22): 12877-82.
50. Allen M, Sandberg-Wollheim M, Sjogren K, Erlich HA, Petterson U, Gyllensten U. Association of susceptibility to multiple sclerosis in Sweden with HLA class II DRB1 and DQB1 alleles. Hum Immunol 1994; 39(1): 41-8.
51. Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci 1993; 20(1): 17-29.
52. Epplen C, Jackel S, Santos EJ, D'Souza M, Poehlau D, Dotzauer B, et al. Genetic predisposition to multiple sclerosis as revealed by immunoprinting. Ann Neurol 1997; 41(3): 341-52.
53. Saruhan-Direskeneli G, Esin S, Baykan-Kurt B, Ornek I, Vaughan R, Eraksoy M. HLA-DR and -DQ associations with multiple sclerosis in Turkey. Hum Immunol 1997; 55(1): 59-65.
54. Detels R, Visscher BR, Malmgren RM, Coulson AH, Lucia MV, Dudley JP. Evidence for lower susceptibility to multiple sclerosis in Japanese-Americans. Am J Epidemiol 1977; 105(4): 303-10.
55. Poser CM, Brinar VV. Diagnostic criteria for multiple sclerosis: an historical review. Clin Neurol Neurosurg. 2004; 106(3): 147-58.
56. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46(4): 907-11.
57. Goertsches R, Comabella M, Navarro A, Perkal H, Montalban X. Genetic association between polymorphisms in the ADAMTS14 gene and multiple sclerosis. J Neuroimmunol 2005; 164(1-2): 140-7.
58. Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi M, et al. Primary progressive multiple sclerosis. Brain 1997; 120(6): 1085-96.
59. Stevenson VT, Miller DH, Rovaris M, Barkhof F, Brochet B, Dousset V, et al. Primary and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology 1999; 52(4): 839-45.
60. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995; 13(1): 119-46.
61. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994; 117(4): 759-65.
62. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50(1): 121-7.
63. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol 2005; 4(6): 341-8.
64. Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000; 123(12): 2407-22.
65. Hartung HP, Grossman RI. ADEM: distinct disease or part of the MS spectrum? Neurology 2001; 56(10): 1257-60.
66. Baló J. Leukoencephalitis periaxialis concentrica. Ról Magy Orv Arch 1927; 28: 108-24. Translation in: Arch Neurol Psychiatry Chicago 1928; 19: 242-64.
67. Schilder PF. Zur Kenntnis der sogenannten diffusen Sklerose (über Encephalitis periaxialis diffusa). Zeitschrift für die gesamte Neurologie und Psychiatrie 1912; 10: 1-60.
68. Devic E. Myélite subaiguë compliquée de névrite optique. Bull Méd (Lyon) 1894; 8: 1093-4.
69. Marburg O. Die sogenannte "akute multiple sklerose" (encephalomyelitis periaxialis scleroticans). Jahrb Psychiat 1906; 27: 213-312.
70. Kidd D, Thompson AJ, Kendall BE, Miller DH, McDonald WI. Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. J Neurol Neurosurg Psychiatry 1994; 57(9): 1070-2.
71. Pryse-Phillips W. Twenty questions about multiple sclerosis clinical trials methodologies. Neurol Sci 2001; 22(2): 187-93.
72. Fangerau T, Schimrigk S, Haupts M, Kaeder M, Ahle G, Brune N, et al. Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria. Acta Neurol Scand 2004; 109(6): 385-9.
73. Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: a critique. Neurology 1988; 38(11): 1793-8.
74. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002; 125(8): 1676-95.
75. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997; 42(3): 379-82.
76. Rieckmann P, Toyka KV, Bassetti C, Beer K, Beer S, Buettner U, et al. Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis-new aspects and practical application. J Neurol 2004; 251(11): 1329-39.
77. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8(4): 431-40.
78. Lesko LJ, Atkinson AJ Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001; 41: 347-66.
79. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
80. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 2004; 127(7): 1463-78.
81. Uccelli A, Pedemonte E, Narciso E, Mancardi G. Biological markers of the inflammatory phase of multiple sclerosis. Neurol Sci 2003; 24(5): S271-4.
82. Martin R, Sturzebecher CS, McFarland HF. Immunotherapy of multiple sclerosis: where are we? Where should we go? Nat Immunol 2001; 2(9): 785-8.
83. Steinman L, Martin R, Bernard C, Conlon P, Oksenberg JR. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci 2002; 25: 491-505.
84. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002; 16(3): 183-200.
85. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8(5): 500-8.
86. Lock CB, Heller RA. Gene microarray analysis of multiple sclerosis lesions. Trends Mol Med 2003; 9(12): 535-41.
87. Mycko, MP, Papoian R, Boschert U, Raine CS, Selmaj KW. cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain 2003; 126(5): 1048-57.
88. Whitney LW, Ludwin SY, McFarland HF, Biddison WE. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J Neuroimmunol 2001; 121(1-2): 40-8.
89. Baranzini SE, Elfstrom C, Chang SY, Butunoi C, Murray R, Higuchi R, et al. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J Immunol 2000; 165(11): 6576-82.
90. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294(5547): 1731-5.
91. Whitney LW, Becker KG, Tresser NJ, Caballero-Ramos CI, Munson PJ, Prabhu VV, et al. Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays. Ann Neurol 1999; 46(3): 425-8.
92. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 2003; 13(4): 554-73.
93. Tajouri L, Mellick AS, Ashton KJ, Tannenberg AE, Nagra RM, Tourtellotte WW, et al. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res Mol Brain Res 2003; 119(2): 170-83.
94. Caillier S, Barcellos LF, Baranzini SE, Swerdlin A, Lincoln RR, Steinman L, et al. Osteopontin polymorphisms and disease course in multiple sclerosis. Genes Immun 2003; 4(4): 312-5.
95. Chiocchetti A, Comi C, Indelicato M, Castelli L, Mesturini R, Bensi T, et al. Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. J Neuroimmunol 2005; 163(1-2): 172-8.
96. Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Blas Navarro J, et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 2005; 158(1-2): 231-9.
97. Lit L, Wong C, Tam L, Li E, Lam C. Elevated plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 23: 602-6.
98. Brown PO, Hartwell L. Genomics and human disease-variations on variation. Nat Genet 1998; 18(2): 91-3.
99. Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, Relman DA, et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA 2003; 100(4): 1896-901.
100. Radich JP, Mao M, Stepaniants S, Biery M, Castle J, Ward T, et al. Individual-specific variation of gene expression in peripheral blood leukocytes. Genomics 2004; 83(6): 980-8.
101. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Moser K, Ortmann WA, et al. Expression levels for many genes in human peripheral blood cells are highly sensitive to ex vivo incubation. Genes Immun 2004; 5(5): 347-53.
102. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Identification of molecularly and clinically distinct types of diffuse large B-cell lymphoma by gene expression profiling. Nature 2000; 403(6769): 503-11.
103. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344(8): 539-48.
104. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194(12): 1861-74.
105. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347(25): 1999-2009.
106. Dalton R. Phoenix rises to genomic challenge. Nature 2002; 417: 107.
107. Stephenson J. Human genome studies expected to revolutionize cancer classification. JAMA 1999; 282(10): 927-8.
108. Vastag B. Gene chips inch toward the clinic. JAMA 2003; 289(2): 155-6, 159.
109. Bammler T, Beyer RP, Bhattacharya S, Boorman GA, Boyles A, Bradford BU, et al. Members of the Toxicogenomics Research Consortium. Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods 2005; 2(5): 351-6.
110. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, et al. Multiple-laboratory comparison of microarray platforms. Nat Methods 2005; 2(5): 345-50.
111. Ramanathan M, Weinstock-Guttman B, Nguyen LT, Badgett D, Miller C, Patrick K, et al. In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J Neuroimmunol 2001; 116(2): 213-9.
112. Maas K, Chan S, Parker J, Slater A, Moore J, Olsen N, et al. Cutting edge: molecular portrait of human autoimmune disease. J Immunol 2002; 169(1): 5-9.
113. Bomprezzi R, Ringner M, Kim S, Bittner ML, Khan J, Chen Y, et al. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet 2003; 12(17): 2191-9.
114. Achiron A, Gurevich M, Friedman N, Kaminski N, Mandel M. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol 2004; 55(3): 410-7.
115. Achiron A, Gurevich M, Magalashvili D, Kishner I, Dolev M, Mandel M. Understanding autoimmune mechanisms in multiple sclerosis using gene expression microarrays: treatment effect and cytokine-related pathways. Clin Dev Immunol 2004; 11(3-4): 299-305.
116. Iglesias AH, Camelo S, Hwang D, Villanueva R, Stephanopoulos G, Dangond F. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J Neuroimmunol 2004; 150(1-2): 163-77.
117. Koike F, Satoh J, Miyake S, Yamamoto T, Kawai M, Kikuchi S, et al. Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. J Neuroimmunol 2003; 139(1-2): 109-18.
118. Weinstock-Guttman B, Badgett D, Patrick K, Hartrich L, Santos R, Hall D, et al. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 2003; 171(5): 2694-702.
119. Airla N, Luomala M, Elovaara I, Kettunen E, Knuutila S, Lehtimaki T. Suppression of immune system genes by methylprednisolone in exacerbations of multiple sclerosis. Preliminary results. J Neurol 2004; 251(10): 1215-9.
120. Serrano-Fernández P, Möller S, Koczan D, Ibrahim SM, Zettl UK. Time course transcriptomics of IFNb therapy. Mult Scler 2004; 10(4): S243.
121. Koczan D, Goertsches R, Serrano-Fernández P, Ibrahim SM, Moeller S, Thiesen HJ, et al. Interferon beta-1a (IM) therapy monitoring using genomewide RNA profiling in peripheral mononuclear cells of MS patients. Mult Scler 2005; 1l(1): S80.
122. Beck S, Kelly A, Radley E, Khurshid F, Alderton RP, Trowsdale J. DNA sequence analysis of 66 kb of the human MHC class II region encoding a cluster of genes for antigen processing. J Mol Biol 1992; 228(2): 433-41.
123. Taniguchi T, Takaoka A. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 2002; 14(1): 111-6.
124. Wong P, Severns CW, Guyer NB, Wright TM. A unique palindromic element mediates gamma interferon induction of mig gene expression. Mol Cell Biol 1994; 14(2): 914-22.
125. Lee TH, Klampfer L, Shows TB, Vilcek J. Transcriptional regulation of TSG6, a tumor necrosis factor-and interleukin-1-inducible primary response gene coding for a secreted hyaluronan-binding protein. J Biol Chem 1993; 268(9): 6154-60.
126. Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol 2004; 152(1-2): 126-39.
127. Mandel M, Gurevich M, Pauzner R, Kaminski N, Achiron A. Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin Exp Immunol 2004; 138(1): 164-70.
128. Satoh J, Nakanishi M, Koike F, Miyake S, Yamamoto T, Kawai M, et al. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol Dis 2005; 18(3): 537-50.
129. Iizaka M, Furukawa Y, Tsunoda T, Akashi H, Ogawa M, Nakamura Y. Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun 2002; 292(2): 498-512.
130. Zhang S, Day IN, Ye S. Microarray analysis of nicotine induced changes in gene expression in endothelial cells. Physiol Genomics 2001; 5(4): 187-92.
131. Mayfield RD, Lewohl JM, Dodd PR, Herlihy A, Liu J, Harris RA. Patterns of gene expression are altered in the frontal and motor cortices of human alcoholics. J Neurochem 2002; 81(4): 802-13.
132. Wang DY, Fulthorpe R, Liss SN, Edwards EA. Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIGI. Mol Endocrinol 2004; 18(2): 402-11.
133. Homo-Delarche F, Fitzpatrick F, Christeff N, Nunez EA, Bach JF, Dardenne M. Sex steroids, glucocorticoids, stress and autoimmunity. J Steroid Biochem Mol Biol 1991; 40(4-6): 619-37.
134. Teuscher C, Bunn JY, Fillmore PD, Butterfield RJ, Zachary JF, Blankenhorn EP. Gender, age, and season at immunization uniquely influence the genetic control of susceptibility to histopathological lesions and clinical signs of experimental allergic encephalomyelitis: implications for the genetics of multiple sclerosis. Am J Pathol 2004; 165(5): 1593-602.
135. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995(5235); 270: 467-70.
136. Schena M, Shalon D, Heller R, Chai A, Brown PO, Davis RW. Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci USA 1996; 93(20): 10614-9.
137. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996; 14(13): 1675-80.
138. Staudt LM, Brown PO. Genomic views of the immune system. Annu Rev Immunol 2000; 18: 829-59.
139. Draghici S. Statistical intelligence: effective analysis of high-density microarray data. Drug Discov Today 2002: 7(l1): S55-63.
140. Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J. Independence and reproducibility across microarray platforms. Nat Methods 2005 2(5): 337-44.
141. Westfall PH, Young SS. In: Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment, Eds. New York, John Wiley & Sons 1993.
142. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B 1995; 57: 289-300.
143. Butte A. The use and analysis of microarray data. Nat Rev Drug Discov 2002; 1(12): 951-60.
144. Wiendl H, Lehmann HC, Hohlfeld R, Hartung HP, Kieseier BC. Multiple sclerosis: potential therapeutic options and update of ongoing studies. Nervenarzt 2004; 75(6): 536-52.
145. Hohol MJ, Olek MJ, Orav EJ, Stazzone L, Hafler DA, Khoury SJ, et al. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/ methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler 1999; 5(6): 403-9.
146. Drews J, Ryser S. The role of innovation in drug development. Nat Biotechnol 1997; 15(13): 1318-19.
147. International Human Genome Mapping Consortium. A physical map of the human genome. Nature 2001; 402(6822): 934-41.
148. Druker, B J. Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol 2003, 40(1): 50-8.
149. Perou CM. Show me the data! Nat Genet 2001; 29(4): 373.
150. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2(2): 85-95.
151. Soen Y, Chen DS, Kraft DL, Davis MM, Brown PO. Detection and characterization of cellular immune responses using peptide-MHC microarrays. PLoS Biol 2003; 1(3): E65.
152. Stone JD, Demkowicz WE Jr, Stern LJ. HLA-restricted epitope identification and detection of functional T cell responses by using MHC-peptide and costimulatory microarrays. Proc Natl Acad Sci USA 2005; 102(10): 3744-9.
153. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ, et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 2002; 8(3): 295-301.
154. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339(5): 285-91.
155. Vukusic, S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127(6): 1353-60.
156. Matejuk A, Dwyer J, Zamora A, Vandenbark AA, Offner H. Evaluation of the effects of 17beta-estradiol (17beta-e2) on gene expression in experimental autoimmune encephalomyelitis using DNA microarray. Endocrinology 2002; 143(1): 313-9.
157. Frueh FW, Gurwitz D. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 2004; 5(5): 571-9.
158. David SP. Pharmacogenetics. Prim Care 2004; 31(3): 543-59.
159. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 2004; 3(9): 739-48.
160. Baranzini SE, Oksenberg JR. Genomics and new targets for multiple sclerosis. Pharmacogenomics 2005; 6(2): 151-61.
161. Kappos L, Achtnichts L, Dahlke F, Kuhle J, Naegelin Y, Sandbrink R, et al. Genomics and proteomics: role in the management of multiple sclerosis. J Neurol 2005; 252(S3): iii21-iii27.
162. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33: S245-54.
163. Barger SW, Moerman AM, Mao X. Molecular mechanisms of cytokine-induced neuroprotection: NFkappaB and neuroplasticity. Curr Pharm Des 2005; 11(8): 985-98.
164. Czlonkowska A, Ciesielska A, Gromadzka G, Kurkowska-Jastrzebska I. Estrogen and cytokines production - the possible cause of gender differences in neurological diseases. Curr Pharm Des 2005; 11(8): 1017-30.
165. Rodi D, Couture R, Ongali B, Simonato M. Targeting kinin receptors for the treatment of neurological diseases. Curr Pharm Des 2005; 11(10): 1313-26.